In addition, PEITC treatments attenuated the transcription factor Sp1 and its downstream target, a drug efflux transporter protein P-gp, which further supports a potential role for PEITC in targeting therapy-resistant CSCs in the context of cervical cancer. Here, PGP is linked to cervical carcinoma.